Whether sitting on a pile of cash or guarding against growing pressures, acquisitions are the answer.
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.
Staffing levels changed little across 2020 as M&A slowed – but sales are another story.
Welcome to the calm before the Covid-19 storm.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
2019 was an average year for medtech M&A. 2020, not so much.